Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evidence-Based Treatments for Alcohol Dependence

Evidence-Based Treatments for Alcohol Dependence COMMENTARY/EDITORIALS 8. Mendelsohn AB, Governale L, Trontell A, Seligman P. Changes in isotretinoin 14. US General Accounting Office. FDA Drug Review: Postapproval Risks 1976-85. prescribing before and after implementation of the System to Manage Accutane Washington, DC: US General Accounting Office; April 1990:24. Publication GAO/ Related Teratogenicity (SMART) risk management program. Pharmacoepidemiol PEMD-90-15. Drug Saf. 2005;14:615-618. 15. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 9. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospi- Timing of new black box warnings and withdrawals for prescription medications. talized patients: results of the Harvard Medical Practice Study II. N Engl J Med. JAMA. 2002;287:2215-2220. 1991;324:377-384. 16. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety dis- 10. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Dav- continuations in the United Kingdom, the United States, and Spain from 1974 ies DM, ed. Textbook of Adverse Drug Reactions. Oxford, England: Oxford Uni- through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108-117. versity Press; 1977:44. 17. Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye’s syndrome and medica- 11. Califf RM. The need for a national infrastructure to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Evidence-Based Treatments for Alcohol Dependence

JAMA , Volume 295 (17) – May 3, 2006

Loading next page...
 
/lp/american-medical-association/evidence-based-treatments-for-alcohol-dependence-QxnbijbFKB

References (7)

Publisher
American Medical Association
Copyright
Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.295.17.2075
pmid
16670416
Publisher site
See Article on Publisher Site

Abstract

COMMENTARY/EDITORIALS 8. Mendelsohn AB, Governale L, Trontell A, Seligman P. Changes in isotretinoin 14. US General Accounting Office. FDA Drug Review: Postapproval Risks 1976-85. prescribing before and after implementation of the System to Manage Accutane Washington, DC: US General Accounting Office; April 1990:24. Publication GAO/ Related Teratogenicity (SMART) risk management program. Pharmacoepidemiol PEMD-90-15. Drug Saf. 2005;14:615-618. 15. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 9. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospi- Timing of new black box warnings and withdrawals for prescription medications. talized patients: results of the Harvard Medical Practice Study II. N Engl J Med. JAMA. 2002;287:2215-2220. 1991;324:377-384. 16. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety dis- 10. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Dav- continuations in the United Kingdom, the United States, and Spain from 1974 ies DM, ed. Textbook of Adverse Drug Reactions. Oxford, England: Oxford Uni- through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108-117. versity Press; 1977:44. 17. Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye’s syndrome and medica- 11. Califf RM. The need for a national infrastructure to

Journal

JAMAAmerican Medical Association

Published: May 3, 2006

There are no references for this article.